Xencor, Inc Other than Temporary Impairment Losses, Investments
Xencor, Inc (XNCR) reported Other than Temporary Impairment Losses, Investments of $762.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfInvestments · last filed 2022-02-24
- Xencor, Inc other than temporary impairment losses, investments for the quarter ending 2021-12-31 was $199.00K.
- Xencor, Inc other than temporary impairment losses, investments for the quarter ending 2021-09-30 was $600.00K.
- Xencor, Inc other than temporary impairment losses, investments for fiscal 2021 was $762.00K.
| Period end | Other than Temporary Impairment Losses, Investments 3 month | Other than Temporary Impairment Losses, Investments 6 month | Other than Temporary Impairment Losses, Investments 9 month | Other than Temporary Impairment Losses, Investments 12 month |
|---|---|---|---|---|
| 2021-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $799.00K derived: sum of 2 quarters · filed 2022-02-24 | $762.00K 10-K · filed 2022-02-24 | |
| 2021-09-30 | $600.00K 10-Q · filed 2021-11-08 | $563.00K 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |